A prospective randomized, double-blind, placebo-controlled, multi-center phase IIb study to evaluate the efficacy and safety of mocravimod in acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic stem cell transplant (HSCT) (MO-TRANS (PKRPCOO1))

Principal Investigator

Kirsty Sharplin

Contact us

Email: Latephasehaematology@ouh.nhs.uk

IRAS number

1004810